treatment considerations in alk/ros-1–rearranged nsclc
Published 5 years ago • 150 plays • Length 3:55Download video MP4
Download video MP3
Similar videos
-
4:43
upfront therapy for alk/ros1-rearranged nsclc
-
4:55
ros1-rearranged nsclc
-
3:15
ros1 rearrangements in mnsclc
-
5:30
sequencing therapy in alk/ros1-rearranged nsclc
-
9:33
second-line brigatinib for alk/ros1-rearranged nsclc
-
3:31
alk/ros1-rearranged nsclc: approaching therapy
-
9:33
second-line brigatinib for alk/ros1-rearranged nsclc
-
4:05
the evolution of alk/ros1-targeted therapy in nsclc
-
6:30
treatment options for alk/ros1 mutation
-
1:27
dr. ou on the use of crizotinib in patients with ros1-rearranged nsclc
-
1:53
ros-1 rearrangements: what are they?
-
2:37
upfront treatment of ros1-rearranged nsclc
-
4:49
emerging alk/ros1 tkis for nsclc
-
6:01
current management of ros1 rearranged nsclc
-
1:51
dr. riess on ros1 fusions in lung cancer
-
2:29
dr. ross camidge discusses crizotinib in ros1 rearranged nsclc
-
8:15
alex trial: frontline therapy for alk-rearranged nsclc
-
1:55
multiple therapies show responses in lung cancer with ros1 fusions
-
1:09
dr. camidge on crizotinib as a ros1 inhibitor in nsclc